Curaleaf Reports Q2 2026 Revenue Growth of 10% and Improved Margins Curaleaf Holdings announced its second quarter 2026 financial results, with revenue rising 10% to $340.1 million, driven by growth in both domestic and international segments. The company also highlighted retail expansion, new product launches, and strategic acquisitions. Curaleaf Holdings reported its financial and operating results for the second quarter ended June 30, 2026. The company posted net revenue of 340.1 million, a 10 percent increase from 310.6 million in the same period last year. Chairman and CEO Boris Jordan said the results reinforce the effectiveness of its Built for Growth strategy, a framework focused on customer centricity, brand building, and operational excellence. He noted that domestic revenue grew 7 percent while international revenue surged 26 percent, and pointed to the second consecutive quarter of domestic year-over-year growth as evidence that the company's reset is durable.Gross profit reached 169.9 million, with a gross margin of 50 percent, up 70 basis points from the prior year. Adjusted EBITDA was 70 million, representing a 21 percent margin. Net income from continuing operations attributable to shareholders was 12.5 million, or 5 cents per share. The company ended the quarter with 107 million in cash and 611.5 million in outstanding debt, net of unamortized discounts and fees.During the first half of 2026, capital expenditures totaled 32.9 million, directed toward facility upgrades, automation, and selective retail expansion in strategic markets. On the operational front, Curaleaf expanded its Florida retail footprint to 73 dispensaries with new openings in Jacksonville Beach and Fernandina Beach, bringing the total operated and managed locations to 174 nationwide. The company launched Dark Heart, its ultra-premium flower brand, across 11 states to strong consumer reception.It also completed the buyout of the remaining 45 percent equity interest in Four20 Pharma, its German subsidiary, giving it 100 percent ownership of Curaleaf International. Additionally, Torsten Greif and Faith Charles were appointed to the board of directors, and Curaleaf Spain became the first company to receive approval for two cannabis medicines. Later in the quarter, two more Florida dispensaries opened in Edgewater and Boynton Beach, raising the retail total to 176.For the six months ended June 30, 2026, net revenue totaled 664.3 million, up 8 percent from 617.2 million in the same period of 2025. Net income from continuing operations for the first half was 82.6 million, or 32 cents per share. Basic weighted average shares outstanding were approximately 263 million for the quarter and 261 million for the six-month period.The company will host a conference call and audio webcast for investors on Wednesday, August 5, 2026 at 5:00 P.M. Eastern Time to discuss the results. The call can be accessed by dialing 1-844-512-2926 in North America or 1-412-317-6300 internationally, with conference pin number 5908337